Status:
COMPLETED
The Potential of Patient-reported Outcome Measures in Detection of Relapse in Diffuse Large B-cell Lymphoma
Lead Sponsor:
Herlev Hospital
Conditions:
Diffuse Large B Cell Lymphoma
Patient Reported Outcome
Eligibility:
All Genders
18+ years
Brief Summary
Annually some 450 patients are diagnosed with Diffuse Large B-cell Lymphoma (DLBCL), in Denmark. The majority of these patients are cured with immunochemotherapy, but up to 30 % will relapse, pointing...
Detailed Description
In the Western world, DLBCL is the most common subtype of non-Hodgkin lymphoma (NHL). In Denmark, approximately 450 patients are diagnosed with DLBCL every year. Treatment with anthracycline-based imm...
Eligibility Criteria
Inclusion
- DLBCL diagnosed according to the WHO classification
- Age \>18 years at diagnosis
- Completed curative intent first line treatment with anthracycline-containing immuno-chemotherapy with or without consolidating radiotherapy and achieved CR on end-of-treatment CT/PET-CT scan, as recorded in the medical record by the treating physician.
- Participated in less than 2 years of follow-up without biopsy-verified relapse
- Access to electronic communication with health authorities (e-Boks - an electronic, closed two factor authentication)
- Able to receive an email and complete a questionnaire in Danish
Exclusion
- Verified lymphoma in the central nervous system (CNS)
- Initial treatment not completed
- CR not reached after initial treatment
- Palliative treatment including attenuated chemotherapy
- Undergoing anti-lymphoma treatment or treatment for other cancer.
- Inability to read Danish or no access to electronic communication
Key Trial Info
Start Date :
February 10 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 30 2023
Estimated Enrollment :
250 Patients enrolled
Trial Details
Trial ID
NCT04695366
Start Date
February 10 2021
End Date
April 30 2023
Last Update
February 28 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Therese Lassen
Copenhagen, Denmark, 2100